NCT03530215View on ClinicalTrials.gov

Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)

CompletedOBSERVATIONAL

Enrollment

500,000

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

May 1, 2022

Study Completion Date

April 8, 2023

Conditions

Cardiac DiseaseCancer

Interventions

DRUG

Antineoplastic and Immunomodulating Agents

Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L

Trial Locations (1)

75013

AP-HP, Pitié-Salpêtrière Hospital,Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM., Paris

All Listed Sponsors

lead

Groupe Hospitalier Pitie-Salpetriere

OTHER

NCT03530215 - Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA) | Biotech Hunter | Biotech Hunter